The Royal Marsden NHS Foundation Trust
RMH - CAR-T Treatment
The procurement contact named on the official notice.
CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients.
The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT).
The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.
What the supplier must deliver
The product should meet strict NHS England
The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.
Derived from the notice text — always confirm against the original documents.
Make the case to bid
Reveal who to approach at The Royal Marsden NHS Foundation Trust, and generate a go-to-market strategy from their news, accounts and people.
- OCID
- ocds-h6vhtk-05d335
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 068116-2025
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
The Royal Marsden NHS Foundation Trust’s tender network
Assembling the network…